{
    "Trade/Device Name(s)": [
        "Randox CSF Controls Levels 2 and 3"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K132156",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040280"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "October 23, 2013",
    "Summary Letter Received Date": "September 9, 2013",
    "Submission Date": "September 6, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Albumin",
        "Alpha-1-globulin",
        "Alpha-2-globulin",
        "Beta-globulin",
        "Gamma-globulin",
        "Chloride",
        "Glucose",
        "Immunoglobulin G",
        "Lactate",
        "Total Protein",
        "Sodium"
    ],
    "Specimen Type(s)": [
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Electrophoresis",
        "Glucose Oxidase",
        "Glucose Hexokinase"
    ],
    "Methodologies": [
        "Electrophoresis"
    ],
    "Submission Type(s)": [
        "Control",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Randox CSF Controls Levels 2 and 3, assayed quality control materials for monitoring precision in clinical chemistry systems with CSF samples",
    "Indications for Use Summary": "For in vitro diagnostic use as assayed quality control material to monitor the precision of diagnostic methods using CSF as a sample on clinical chemistry systems",
    "fda_folder": "Clinical Chemistry"
}